BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
8.3050
+0.3550 (4.47%)
NASDAQ · Last Trade: Aug 4th, 12:18 PM EDT
Detailed Quote
Previous Close
7.950
Open
9.140
Bid
8.300
Ask
8.310
Day's Range
8.095 - 9.140
52 Week Range
6.015 - 11.31
Volume
4,630,878
Market Cap
1.54B
PE Ratio (TTM)
-31.94
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
3,386,326
Chart
About BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)
Biocryst Pharma is a biotechnology company focused on developing and commercializing innovative treatments for rare diseases. The company specializes in designing and synthesizing novel small-molecule drugs, particularly those targeting diseases associated with viral infections and genetic disorders. With a commitment to improving patient outcomes, Biocryst employs cutting-edge research and clinical development strategies to bring effective therapies to market, aiming to address unmet medical needs in challenging therapeutic areas. Read More
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year.
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up to $14 million in future milestone payments.
BIOCRYST PHARMACEUTICALS (NASDAQ:BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
BIOCRYST PHARMACEUTICALS (BCRX) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors.
BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
